Chemotherapy in elderly gynecologic cancer patients aged over 70 years: Facts and controversies

Women's Oncology Review

Volumn 2, Issue 4, 2002, Pages 385-394

  Ceccaroni, Marcello ^a   De Iaco, Pierandrea ^a   Scambia, Giovanni ^b   Bovicelli, Luciano ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIPODOPHYLLOTOXIN; EPIRUBICIN; ERYTHROPOIETIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; IRINOTECAN; MELPHALAN; METHOTREXATE; MITOXANTRONE; PACLITAXEL; TAXANE DERIVATIVE; TOPOTECAN; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

AGED; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CARDIOTOXICITY; COMORBIDITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; FEMALE; GERIATRIC CARE; GYNECOLOGIC CANCER; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; NEUROTOXICITY; REVIEW;

EID: 0036965451     PISSN: 14733404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Aapro MS. Geriatric oncology still has a long way to go. Oncology In Practice 98;2:2
2. Boyle P. Trends in cancer mortality in Europe. Eur J Cancer 1992;28:7-8
3. Lesur A, Rios M. Evaluation of elderly patients for fitness to receive treatment. Oncology In Practice 98;2:9-11
4. Silvermann MA, Temple JD. Cancer in the elderly patient. Unique aspects of presentation, management and screening. J Fla Med Assoc 1992;79:89-92
5. Thyss A, Saudes L, Otto J, et al. Renal tolerance of cisplatin in patients more than 80 years old. J Clin Oncol 1994;12:2121-5
6. Susini T, Scambia G, Margariti PA, et al. Gynecologic oncologic surgery in the elderly: a retrospective analysis of 213 patients. Gynecol Oncol 1999;75:437-43
7. Giannice R, Susini T, Ferrandina G, et al. Systematic pelvic and aortic lymphadenectomy in elderly gynecologic oncologic patients. Cancer 2001;92:2562-8
8. Parant A. Le vieillissement dèmographique en France. La documentation francaise. Regards sur l'actualité 1996;220-1
9. Lesur A, Rios M. Epidémiologie descriptive du cancer du sein de la femme de plus de 70 ans. 19ème Journées Nationales de la Société Francaise de Sènologie et de Pathologie Mammaire, Avignon, France. 1997;23-33
10. Conte PF, Romanini A, Brunetti I, et al. Ovarian cancer in elderly women. Int J Gynecol Cancer 1997;7(Suppl. 1):23-6
11. Pignata S, Monfardini S. Single agents should be administered in preference to combination chemotherapy for the treatment of patients over 70 years of age with advanced ovarian carcinoma. Eur J Cancer 2000;36:817-20
12. Fentiman IS, Tirelli U, Monfardini S, et al. Cancer in the elderly: why so badly treated? Lancet 1990;335:1020-2
13. Fentiman IS. Denying surgery to elderly people with cancer. Oncology In Practice 98;2:12
14. Berkman B, Rohan B, Sampson S. Myths and biases related to cancer in the elderly. Cancer 1994;74:2004-8
15. Martin W, Corner J. Barriers to early cancer treatment for elderly people. Oncology In Practice 98;2:3
16. Chiara S, Lionetto R, Vincenti M, et al. Advanced ovarian cancer in the elderly: results of consecutive trials with cisplatin-based chemotherapy. Crit Rev Oncol Hematol 2001;37:27-34
17. Serraino D, Fratino L. Ageing and cancer: the epidemiological point of view. Tumori 2002;88(Suppl. 1):S7-8
18. World Health Organization-WHO. World Health Statistics Annual. Geneva: WHO, 1987
19. Cohen HJ. Cancer and the functional status of the elderly. Cancer 1997;80:1883-6
20. Hill C, Doyon F, Sancho-Garnier H. Epidémiologie des Cancers. Paris: Flammarion. 1997:16-25
21. Extermann M. Comorbidity and geriatric assessment in the elderly patient over the age of 70. Tumori 2002;88(Suppl. 1):S9
22. Markman M, Lewis JL, Saigo P, et al. Epithelial ovarian cancer in the elderly: the Memorial Sloan-Kettering Cancer Center experience. Cancer 1993;71(Suppl. 2):634-7
23. Newell GR, Spitz MR, Sider JG. Cancer and age. Semin Oncol 1989;16:3-9
24. Nicoletto MO, Artioli G, Donach M, et al. Elderly ovarian cancer: treatment with mitoxantrone-carboplatin. Gynecol Oncol 2001;80:221-6
25. Edmonson JH, Su J, Krook JE. Treatment of ovarian cancer in elderly women: Mayo Clinic-North Central Cancer Treatment Group Studies. Cancer 1993;71:615-7
26. Aapro M, Extermann M, Repetto L. Evaluation of the elderly with cancer. Ann Oncol 2000;11(Suppl. 3):223-9
27. Monfardini S, Sorio R, Hoctin Boes G, et al. Entry and evaluation of elderly patients in European Organization for Research and Treatment of Cancer (EORTC) new drug development study. Cancer 1995;76:333-8
28. Yancik R, Ries LG. Cancer in the aged: an epidemiologic perspective on treatment issues. Cancer 1991;68(Suppl. 11):2502-10
29. Ceccaroni M, D'Agostino G, Ferrandina G, et al. Gynecological malignancies in elderly patients: is age 70 a limit to standard-dose chemotherapy? An Italian retrospective toxicity multicentric study. Gynecol Oncol 2002;85:445-50
30. Monfardini S, Ferrucci L, Fratino L, et al. Validation of a multidimensional evaluation scale for use in elderly cancer patients. Cancer 1996;77:395-401
31. Balducci L, Parker M, Sexton W, et al. Pharmacology of antineoplastic agents in the elderly patient. Semin Oncol 1989;16:76-84
32. Balducci L, Extermann M. Cancer chemotherapy in the older patient. Cancer 1997;80:1317-22
33. Pearlman DN, Branch LG, Ozminkowski RJ, et al. Transitions in health care use and expenditures among frail older adults. J Am Geriatr Soc 1997;45:550-7
34. Cova D, Beretta G, Balducci L. Cancer chemotherapy in the older patient. In Comprehensive Geriatric Oncology. Balducci L, Lyman GH, Ershler WB, eds. London: Hardwood Academic Press, 1998:429-41
35. Kimmik G, Fleming R, Muss H, et al. Cancer chemotherapy in older adults: a tolerability perspective. Drugs Aging 1997;10:34-49
36. Baker SD, Grochow LB. Pharmacology of cancer chemotherapy in the older person. Clin Geriatr Med 1997;13:169-84
37. Ershler WB, Longo D. Aging and cancer: issues of basic and clinical science. J Natl Cancer Inst 1997;89:1489-97
38. Campisi J. Aging and cancer: the double-edged sword of proliferative senescence. J Am Geriatr Soc 1997;45:482-8
39. Balducci L, Extermann M. Difficulties in treating older patients with cancer. Oncology In Practice 98;2:15
40. Daidone MG, Luisi A, Silvestrini R, et al. Biologic characteristics of primary breast cancer in the elderly. In Comprehensive Geriatric Oncology. Balducci L, Lyman GH, Ershler WB, eds. London: Hardwood Academic Press, 1998:197-200
41. Yamamoto N, Tamura T, Maerla M, et al. The influence of aging on cisplatin pharmacokinetics in lung cancer patients with normal organ function. Cancer Chemother Pharmacol 1995;36:102-6
42. Sotariano WA, Ragland DA. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 120:104-10
43. Egorin MJ. Cancer pharmacology in the elderly. Semin Oncol 1993;20:43-9
44. Durnas C, Loi C, Cusack BJ. Hepatic drug metabolism and aging. Clin Pharmacokinetic 1990;17:236-63
45. Burkowski JM, Duerr M, Donehower RC, et al. Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data. Cancer Chemother Pharmacol 1994;33:493-6
46. Begg CB, Elson PJ, Carbone PP. A study of excess hematologic toxicity in elderly patients treated on cancer chemotherapy protocols. In Cancer in the Elderly. An Approach to Early Detection and Treatment. Yancik K, Yates JW, eds. New York: Springer Verlag 1989:149-63
47. Giovanazzi-Borman S, Rademaker A, Loi G, et al. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center Study. J Clin Oncol 1994;12:2447-52
48. Arbuck SG, Strauss H, Rowinsky E, et al. A reassessment of cardiac toxicity associated with Taxol. Monogr Natl Cancer Inst 1993;15:117-30
49. Ceccaroni M, D'Agostino G, Ferrandina G, et al. Gynecological malignancies in elderly patients: is age 70 a limit to standard-dose chemotherapy? An Italian retrospective toxicity multicentric study. Eur J Gynaecol Oncol 2001;22(Suppl.):abstr. 122
50. Hightower RD, Nguyen HN, Averette HE, et al. National survey of ovarian carcinoma IV. Patterns of care and related survival for older patients. Cancer 1994;73:377-83
51. Adkins RB, Scott W. Surgical procedures in patients aged 90 years and older. South Med J 1984;77:1357-64
52. Bicher A, Sarosy G, Kohn E, et al. Age does not influence taxol dose intensity in recurrent carcinoma of the ovary. Cancer 1993;71:594-600
53. Ries LAG. Ovarian cancer: survival and treatment differences by age. Cancer 1993;71:524-9
54. Higgins RV, Naumann RW, Gardner J, et al. Is age a barrier to the aggressive treatment of ovarian cancer with paclitaxel and carboplatin? Gynecol Oncol 1999;75:464-7
55. Del Mastro L, Maggi E, Catzeddu T, et al. Is it possible to use anthracyclines in patients older than 70 years? Contra Tumori 2002;88(Suppl. 1):S136-7
56. Ibrahim NK, Hortobagyi GN, Ewer M, et al. Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience. Cancer Chemother Pharmacol 1999;43:471-8
57. Bernardi D. Is it possible to use anthracyclines in patients older than 70 years? Tumori 2002;88(Suppl. 1):S133-5
58. Arias F, Duenas M, Martinez E, et al. Radical chemotherapy for elderly patients with bladder carcinoma invading muscle. Cancer 1997;80:115-20
59. Sarosy G, Kohn E, Stone DA, et al. Phase I study of taxol and G-CSF in patients with refractory ovarian cancer. J Clin Oncol 1992;10:1165-70
60. Walsh SJ, Begg CB, Carbone PP. Cancer chemotherapy in the elderly. Semin Oncol 1989;16:66-75
61. Begg CB, Carbone PP. Clinical trials and drug toxicity in the elderly: the experience of the Eastern Cooperative Oncology Group. Cancer 1983;52:1986-92
62. Alberts DS, Green S, Hanningan E, et al. Improved therapeutic index of carboplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992;10:706-17
63. Gershenson DM, Follen Mitchell M, Atkinson N, et al. Age contrasts in patients with advanced epithelial ovarian cancer: the M.D. Anderson Cancer Center experience. Cancer 1993;71:638-43
64. Balducci L, Mowry K. Pharmacology and organ toxicity of chemotherapy in older patients. Oncology 1992;6:62-8
65. Lipschitz DA. Age-related declines in hemathopoietic reserve capacity. Semin Oncol 1995;22:3-5
66. Nordin AJ, Chinn DJ, Moloney I, et al. Do elderly cancer patients care about cure? Attitudes to radical gynecologic oncology surgery in the elderly. Gynecol Oncol 2001;81:447-55